<DOC>
	<DOCNO>NCT00006024</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one chemotherapy drug radiation therapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness temozolomide plus lomustine follow radiation therapy treat patient high-grade malignant glioma .</brief_summary>
	<brief_title>Temozolomide Plus Lomustine Followed Radiation Therapy Treating Patients With High-Grade Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose temozolomide administer lomustine patient high-grade malignant glioma . - Determine dose-limiting toxic effect regimen patient . - Evaluate feasibility radiotherapy treatment regimen patient population . - Evaluate radiographic response patient treat regimen . OUTLINE : This multicenter , dose-escalation study temozolomide . Patients receive oral temozolomide day 1-5 oral lomustine day 1 . Treatment continue every 28 day , blood count recover , 2 course absence disease progression unacceptable toxicity . Patients undergo radiotherapy day 1-5 weekly 6 week . Patients continue chemotherapy regimen 6 course begin 4 week completion radiotherapy . Cohorts 3-6 patient receive escalate dos temozolomide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 3-30 patient accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm highgrade malignant glioma one follow subtypes : Glioblastoma Anaplastic astrocytoma Anaplastic oligoastrocytoma Gliomatosis cerebri No disseminated disease primary spinal cord malignancy Measurable intracranial residual disease MRI PATIENT CHARACTERISTICS : Age : 3 Under 22 time diagnosis Performance status : Karnofsky 50100 % 10 year age Lansky 50100 % 10 year age Life expectancy : At least 8 week Hematopoietic : Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 ( transfusion independent ) Hemoglobin least 8.0 g/dL ( RBC transfusion allow ) Hepatic : Bilirubin great 1.5 time normal age SGPT great 2.5 time normal age Albumin least 2 g/dL Renal : Creatinine great 1.5 time normal age OR Creatinine clearance radioisotope glomerular filtration rate least low limit normal age Pulmonary : No dyspnea rest No exercise intolerance Pulse oximetry least 94 % Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy No concurrent prophylactic hematopoietic growth factor Chemotherapy : No prior chemotherapy Endocrine therapy : Prior corticosteroid therapy allow No concurrent corticosteroid antiemetic Radiotherapy : No prior radiotherapy Surgery : No 31 day since prior maximal neurosurgical procedure Other : No concurrent phenobarbital cimetidine</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
</DOC>